In The Nick Of Time: Xbrane Picks Up Intas As Global Nivolumab Partner
Swedish Biosimilars Developer Beats Deal Deadline For Opdivo Rival
Having previously set itself a deadline of the end of November to strike a licensing deal for one of two biosimilar candidates – or risk failing to meet its working capital requirements – Sweden’s Xbrane has now announced a global licensing partnership with Intas for its nivolumab Opdivo rival, with just days to spare.
